Health Care·Biotechnology·$6.4B
Protagonist Therapeutics (PTGX) operates in the biotechnology sector, focusing on developing novel therapies for serious diseases. With a market cap of $6 billion, the company is significant in the healthcare landscape, especially as it works on innovative treatments that could impact patient care and market dynamics.
EPS
Earnings per share is crucial as it reflects the company's profitability and operational efficiency.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
50%
Avg EPS Surprise
+387.64%
Avg Stock Reaction
-0.28%
In Q4-2025, Protagonist reported an EPS of -0.69, missing expectations, which led to a slight decline in stock price the following day. The company continues to navigate challenges in revenue reporting, as no revenue figures were disclosed.
Management Promises & Guidance
Analysts expect Protagonist to report a loss this quarter, with a consensus EPS of -0.65 and revenue of $16 million. Investors are closely watching for any signs of recovery in earnings and sales.
Bull Case
If Protagonist can exceed EPS expectations and show stronger revenue growth, it could signal a turnaround in its financial performance, boosting investor confidence.
Bear Case
Conversely, if the company misses on both EPS and revenue, it may raise concerns about its ongoing viability and ability to execute its business strategy.
EPS
-0.65Earnings per share is crucial as it reflects the company's profitability and operational efficiency.
Revenue
16MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will Protagonist achieve an EPS closer to the consensus estimate of -0.65?
A closer EPS to the consensus could indicate improved operational performance and investor sentiment.
Q2
What revenue figures will Protagonist report, and how do they compare to the $16 million consensus?
Revenue performance is critical for assessing market demand and the success of Protagonist's product offerings.
Why consensus could be wrong
The Street may be underestimating Protagonist's potential for a revenue surprise due to recent advancements in its pipeline that have not been fully accounted for.
Supporting Evidence
The company's recent clinical trial results suggest stronger demand for its therapies than analysts expect.
Historical patterns indicate that Protagonist has a 50% EPS beat rate, suggesting potential for positive surprises.
Key Risk
If revenue exceeds $20 million, it could challenge the current bearish sentiment and shift investor expectations.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether Protagonist can stabilize its earnings and revenue after recent misses.
Bull Confirmed If
An EPS of -0.50 or better, along with revenue exceeding $20 million, would confirm the bull case.
Bear Confirmed If
An EPS worse than -1.00 and revenue below $10 million would confirm the bear case.
Implied Move
±4.2%
The options market is pricing in a potential move of 4.2%, indicating that investors expect some volatility around the earnings announcement.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Protagonist beats expectations, history suggests a potential stock increase of about 1.36%, confirming a positive outlook.
In-Line / Cautious
If results are in line but management provides cautious commentary, the stock may react modestly, reflecting uncertainty.
Miss
Should the company miss expectations, history suggests a potential decline of around 0.80%, raising concerns about its future prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026